Hydration Intervention to Decrease Side Effects Associated With GLP - 1 RA Therapy
Registered N/A interventional trial (recruiting). This is a 17 - week study consisting of a one - week run - in period and a 16 - week intervention. The 16 - week pilot interventions aims to increase hydration in those beginning GLP - 1 RA therapy. Investigators aim to increase hydration to potentially decrease side effect severity, amount of side effects, and drug discontinuation associated with GLP - 1 RA therapy. The investigators are piloting to assess feasibility and preliminary efficacy of the intervention through examining participant retention, participant feedback, researcher and part
Registered clinical trial record on ClinicalTrials.gov (NCT07641361). This describes a planned, ongoing, or completed study — it is NOT peer-reviewed results. Status: recruiting. Study type: interventional. Phase: N/A. Sponsor: State University of New York at Buffalo. Conditions: Obesity & Overweight, Type 2 Diabetes, Type 2 Diabetes (Adult Onset), Obesity Type 2 Diabetes Mellitus, Dehydration. Interventions: Hydration Plus, Control. Summary: This is a 17 - week study consisting of a one - week run - in period and a 16 - week intervention. The 16 - week pilot interventions aims to increase hydration in those beginning GLP - 1 RA therapy. Investigators aim to increase hydration to potentially decrease side effect severity, amount of side effects, and drug discontinuation associated with GLP - 1 RA therapy. The investigators are piloting to assess feasibility and preliminary efficacy of the intervention through examining participant retention, participant feedback, researcher and participant adherence to protocols, impact on hydration biomarkers, and participant reported GLP - 1 RA side effects. Primary outcome measures: Acceptability of hydration plus; Feasibility of Intervention; Change in physiological hydration score; Change in perceived hydration level. Eligibility: Inclusion Criteria: * Adults aged 18-60 * Recently prescribed a GLP-1RA (within one week of prescription) * Fluent in English * Willing to complete the study protocol Exclusion Criteria: * Children and adults \> 60 years of age * Those not taking a GLP-1RA * Those who have been on a GLP-1RA longer than one week * Not fluent in English * Those who are pregnant or planning on becoming pregnant during the duration of the study * Unwilling to comply with study protocol * People with cardiac implants
This is a registered clinical-trial record from ClinicalTrials.gov — a description of a planned, ongoing, or completed study, not peer-reviewed results. Listing on ClinicalTrials.gov does not mean the study has been evaluated by the U.S. Federal Government, nor does it imply endorsement or that the intervention is safe or effective.
Educational summary of published research — not medical advice. License: public-domain. Full text is shown only where licensing permits.